患者报告结局是银屑病治疗决策的重要要素:美国皮肤科医生离散选择实验调查
该研究通过两项在线调查(分别纳入130名和129名美国皮肤科医生),采用离散选择实验了解皮肤科医生如何评估生物制剂及权衡规则。结果显示,74%和76%的医生在选择生物制剂时同时使用PASI和PROs;PASI应答率是最重要属性(占决策权重35%-38%),而PROs合计权重相似(36%)。结论认为PASI最重要,但PROs也被考虑,尤其在PASI应答率相似时。
要点
- 多数美国皮肤科医生在选择生物制剂时同时使用PASI和患者报告结局(PROs)。
- PASI应答率是决策中最重要的单一属性,占整体决策权重35%-38%。
- PROs合计权重与PASI相似(36%),在PASI应答率相似时影响治疗选择。
核心结论
- PASI是皮肤科医生选择生物制剂时最重要的属性,但PROs也被考虑,尤其在PASI应答率相似时。
- 建议在中重度银屑病临床试验中收集PRO数据。
研究设计与样本
- 两项在线调查分别纳入130名和129名美国皮肤科医生,采用直接和间接 elicitation 的离散选择实验。
- 受访者基于6个属性(PASI≥75%改善、PASI≥90%改善、感染风险、给药频率及3个PROs:抑郁缓解、瘙痒缓解、对日常活动的影响)选择假设的生物制剂。
主要发现
- 74%(调查1)和76%(调查2)的皮肤科医生报告在选择生物制剂时同时使用PASI和PROs。
- PASI应答率是最重要属性,占整体决策权重的35%-38%。
- PROs合计属性重要性相似,占决策权重的36%。
- 感染风险和给药频率对决策的影响较小。
关键数值与推荐
- PASI应答率占整体决策权重35%-38%,PROs合计占36%。
临床怎么用
- 临床选择生物制剂时应同时关注PASI应答率和患者报告结局(如抑郁、瘙痒、日常活动影响)。
- 当不同治疗PASI应答率相似时,PROs可作为重要的决策依据。
局限性
- 考虑3个PROs对比1个PASI率和1个安全性属性可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis Area and Severity Index (PASI) response rates have been the benchmark for evaluating treatment efficacy in trials involving moderate-to-severe psoriasis. OBJECTIVE: To understand how dermatologists assess biologics and which trade-off rules they apply when planning psoriasis treatment. METHODS: Two online surveys of 130 and 129 US dermatologists (surveys 1 and 2, respectively) were conducted with use of direct and indirect elicitation via discrete choice experiment. Respondents were asked to choose hypothetical biologics on the basis of 6 attributes (a ≥75% reduction from baseline in PASI score or a ≥90% reduction from baseline in PASI score, infection risk, dosing frequency, and 3 patient-reported outcomes [PROs] [relief of depression, relief of itching, and impact on usual activities]). RESULTS: Most dermatologists (74% in survey 1 and 76% in survey 2) reported using both PASI and PROs when selecting a biologic. PASI response rate was the most important attribute (35%-38% of overall decision weight), whereas combined PRO attributes had similar importance (36% of decision weight). Infection risk and dosing frequency influenced the decision to a lesser extent. LIMITATIONS: Potential bias in considering 3 PROs versus 1 PASI rate and 1 safety attribute. CONCLUSION: PASI is most important for dermatologists selecting biologics, but PROs are also considered, especially when PASI response rate is similar between treatments. PRO data should be collected in trials involving moderate-to-severe psoriasis.
引用
- Feldman SR, Regnier SA, Chirilov A, et al. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol. 2019. PMID: 30703461. doi:10.1016/j.jaad.2019.01.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。